Search Results - "Prikrylova Vranova, Hana"

Premotor Parkinson's disease: Overview of clinical symptoms and current diagnostic methods by Kaiserova, Michaela, Grambalova, Zuzana, Kurcova, Sandra, Otruba, Pavel, Prikrylova Vranova, Hana, Mensikova, Katerina, Kanovsky, Petr

“…Parkinson's disease (PD) is characterized by typical motor symptoms. However, recent studies show several non-motor features that may precede the development…”
Get full text

Stable isotope dilution ultra-high performance liquid chromatography–tandem mass spectrometry quantitative profiling of tryptophan-related neuroactive substances in human serum and cerebrospinal fluid by Hényková, Eva, Vránová, Hana Přikrylová, Amakorová, Petra, Pospíšil, Tomáš, Žukauskaitė, Asta, Vlčková, Magdaléna, Urbánek, Lubor, Novák, Ondřej, Mareš, Jan, Kaňovský, Petr, Strnad, Miroslav

“…•Profiling of L-tryptophan (L-TRP) and its related compounds in human bodily fluids.•Simultaneous determination of endogenous L-TRP and its 16 metabolites by…”
Get full text

Cerebrospinal Fluid Levels of 5-Hydroxyindoleacetic Acid in Parkinson's Disease and Atypical Parkinsonian Syndromes by Kaiserova, Michaela, Chudackova, Monika, Prikrylova Vranova, Hana, Mensikova, Katerina, Kastelikova, Anetta, Stejskal, David, Kanovsky, Petr

“…Various cerebrospinal fluid (CSF) biomarkers are studied in Parkinson's disease (PD) and atypical parkinsonian syndromes (APS). Several studies found reduced…”
Get more information

Cerebrospinal Fluid Levels of Chromogranin A in Parkinson's Disease and Multiple System Atrophy by Kaiserova, Michaela, Chudackova, Monika, Mensikova, Katerina, Vastik, Miroslav, Kurcova, Sandra, Prikrylova Vranova, Hana, Stejskal, David, Kanovsky, Petr

“…Chromogranin A (CgA) and other peptides from the chromogranin-secretogranin family have been recently studied as potential biomarkers of various…”
Get full text

Orthostatic hypotension is associated with decreased cerebrospinal fluid levels of chromogranin A in early stage of Parkinson disease by Kaiserova, Michaela, Prikrylova Vranova, Hana, Galuszka, Jan, Stejskal, David, Mensikova, Katerina, Zapletalova, Jana, Mares, Jan, Kanovsky, Petr

“…An association between the CSF chromogranin A (CgA) and orthostatic blood pressure changes was investigated in 20 patients in the early stage of Parkinson…”
Get full text

CSF markers of neurodegeneration in Parkinson’s disease by Přikrylová Vranová, Hana, Mareš, Jan, Nevrlý, Martin, Stejskal, David, Zapletalová, Jana, Hluštík, Petr, Kaňovský, Petr

“…Parkinson’s disease (PD) is a chronic, progressive, neurodegenerative disease with a multifactorial etiology. Protein accumulation is speculated by some to…”
Get full text

Clusterin CSF levels in differential diagnosis of neurodegenerative disorders by Přikrylová Vranová, Hana, Hényková, Eva, Mareš, Jan, Kaiserová, Michaela, Menšíková, Kateřina, Vaštík, Miroslav, Hluštík, Petr, Zapletalová, Jana, Strnad, Miroslav, Stejskal, David, Kaňovský, Petr

“…Abstract Introduction Clusterin, a heterodimeric glycoprotein, is thought to be involved in many cellular functions, including cell–cell interaction, cell…”
Get full text

Cerebrospinal fluid levels of chromogranin A in the treatment-naïve early stage Parkinson’s disease: a pilot study by Kaiserová, Michaela, Vranová, Hana Přikrylová, Stejskal, David, Menšíková, Kateřina, Kaňovský, Petr

“…Chromogranin A (CgA) levels in cerebrospinal fluid (CSF) have been reported to be significantly reduced in the later stages of Parkinson’s disease (PD). There…”
Get full text

Can Inflammatory Markers From CSF Be Helpful In Diagnosis Of Multiple Sclerosis? (P4.137) by Matejcikova, Zuzana, Prikrylova-Vranova, Hana, Klosova, Jana, Sladkova, Vladimira, Zapletalova, Jana, Mares, Jan, Kanovsky, Petr

“…Abstract only…”
Get full text

Decreased Cerebrospinal Fluid Levels of Chromogranin A in Early Stages of Parkinson’s Disease may Predict Earlier Development of Orthostatic Hypotension (P1.266) by Kaiserova, Michaela, Prikrylova Vranova, Hana, Galuszka, Jan, Stejskal, David, Mensikova, Katerina, Zapletalova, Jana, Mares, Jan, Kanovsky, Petr

“…Abstract only…”
Get full text

Clusterin CSF Levels in Differential Diagnosis of Neurodegenerative Disorders (S27.007) by Prikrylova Vranova, Hana, Henykova, Eva, Kaiserova, Michaela, Mensikova, Katerina, Vastik, Miroslav, Mares, Jan, Hlustik, Petr, Zapletalova, Jana, Strnad, Miroslav, Stejskal, David, Kanovsky, Petr

“…Abstract only…”
Get full text

Tau protein, beta-amyloid sub(1-42) and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia by Vranova, Hana Prikrylova, Henykova, Eva, Kaiserova, Michaela, Mensikova, Katerina, Vastik, Miroslav, Mares, Jan, Hlustik, Petr, Zapletalova, Jana, Strnad, Miroslav, Stejskal, David, Kanovsky, Petr

“…Background: Parkinson's disease (PD), PD with dementia (PDD) and Lewy body dementia (DLB) are synucleinopathies. PDD and DLB are sometimes considered a…”
Get full text

Tau protein and beta-amyloid sub(1-42) CSF levels in different phenotypes of Parkinson's disease by Prikrylova Vranova, Hana, Mares, Jan, Hlustik, Petr, Nevrly, Martin, Stejskal, David, Zapletalova, Jana, Obereigneru, Radko, Kaovsky, Petr

“…Parkinson's disease (PD) is a neurodegenerative disorder with highly heterogeneous clinical manifestations. This fact has prompted many attempts to divide PD…”
Get full text

Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease by Přikrylová Vranová, Hana, Mareš, Jan, Hluštík, Petr, Nevrlý, Martin, Stejskal, David, Zapletalová, Jana, Obereigneru, Radko, Kaňovský, Petr

“…Parkinson's disease (PD) is a neurodegenerative disorder with highly heterogeneous clinical manifestations. This fact has prompted many attempts to divide PD…”
Get more information

Tau protein, beta-amyloid1–42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia by Vranová, Hana Přikrylová, Hényková, Eva, Kaiserová, Michaela, Menšíková, Kateřina, Vaštík, Miroslav, Mareš, Jan, Hluštík, Petr, Zapletalová, Jana, Strnad, Miroslav, Stejskal, David, Kaňovský, Petr

“…Abstract Background Parkinson's disease (PD), PD with dementia (PDD) and Lewy body dementia (DLB) are synucleinopathies. PDD and DLB are sometimes considered a…”
Get full text

Cystatin C as a Marker of Degeneration in Multiple Sclerosis (P03.241) by Prikrylová Vranová, Hana, Sládková, Vladimíra, Mareš, Jan, Hluštík, Petr, Langová, Jana, Kanovský, Petr

“…Abstract only…”
Get full text

Tau Protein, beta-Amyloid 1-42 and Clusterin CSF Levels in Differential Diagnosis of Parkinsonian Syndrome with Dementia (P04.156) by Prikrylová Vranová, Hana, Hényková, Eva, Kaiserová, Michaela, Menšíková, Katerina, Vaštík, Miroslav, Mareš, Jan, Hluštík, Petr, Zapletalová, Jana, Strnad, Miroslav, Stejskal, David, Kanovský, Petr

“…Abstract only…”
Get full text

Tau protein and beta-amyloid1-42 CSF levels in different phenotypes of Parkinson’s disease by Přikrylová Vranová, Hana, Mareš, Jan, Hluštík, Petr, Nevrlý, Martin, Stejskal, David, Zapletalová, Jana, Obereigneru, Radko, Kaňovský, Petr

“…Parkinson’s disease (PD) is a neurodegenerative disorder with highly heterogeneous clinical manifestations. This fact has prompted many attempts to divide PD…”
Get full text

Tau protein and beta-amyloid^sub 1-42^ CSF levels in different phenotypes of Parkinson's disease by Prikrylová Vranová, Hana, Mares, Jan, Hlustík, Petr, Nevrlý, Martin, Stejskal, David, Zapletalová, Jana, Obereigneru, Radko, Kaovský, Petr

“…Parkinson's disease (PD) is a neurodegenerative disorder with highly heterogeneous clinical manifestations. This fact has prompted many attempts to divide PD…”
Get full text